Metabolic Syndrome (Investigational Adjunct)

Investigational adjunct to lifestyle modification in metabolic syndrome; small case series only; weight loss, dietary modification, and pharmacotherapy remain primary.

Tier C — InvestigationalInvestigationalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patient Summary

Is this FDA-cleared for this use?: Not FDA-cleared for metabolic syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for metabolic syndrome is investigational.
What evidence exists?: Tier C (investigational). Only anecdotal reports; there are no randomized controlled trials. Evidence-based management of metabolic syndrome per AHA/ACC guidelines: lifestyle modification (weight loss 5-10 percent, Mediterranean or DASH diet, 150 minutes/week aerobic exercise plus resistance training), treatment of individual components (statin for dyslipidemia, ACE inhibitor or ARB for hypertension, metformin or GLP-1 receptor agonist for insulin resistance/prediabetes/type 2 diabetes), and cardiovascular risk stratification.
Main risks: Bleeding from bite sites for 6 to 24 hours after detachment
Worsening of glycemic control or blood pressure
Local skin infection or, rarely, Aeromonas infection (higher risk in diabetes)
Allergic reaction to leech saliva (uncommon)
Delayed wound healing in patients with poorly controlled diabetes
Risk of vasovagal episode in patients with autonomic dysfunction
Substitution for lifestyle modification and proven pharmacologic therapy
Delay of statin, antihypertensive, or GLP-1 receptor agonist therapy
Who should not consider this: Patients with poorly controlled diabetes (HbA1c >9 percent)
Patients with peripheral arterial disease severe stenosis or diabetic foot ulcers
Patients with active cardiovascular event (recent MI, unstable angina, decompensated heart failure)
Patients on anticoagulants, with hemophilia, or with severe anemia
Pregnant patients
Patients who have not engaged with lifestyle modification or evidence-based pharmacotherapy
What to ask your clinician: What is my 10-year cardiovascular risk (ASCVD score)?
Have I been started on appropriate evidence-based therapy (statin, ACE/ARB, metformin, GLP-1)?
Am I a candidate for a GLP-1 receptor agonist for weight loss and cardiovascular protection?
Have I had nutrition and exercise counseling?
What evidence specifically supports leech therapy for metabolic syndrome?
How will treatment be monitored (HbA1c, blood pressure, lipids, weight)?
What is the cost and is it covered by insurance? (typically not covered)
When to seek urgent care: Chest pain, shortness of breath, or pressure (possible cardiac event)
New numbness, weakness, or slurred speech (possible stroke)
Severe abdominal pain (possible pancreatitis from severe hypertriglyceridemia)
Diabetic foot ulcer or new skin breakdown on the feet
Spreading redness, warmth, pus, or red streaks (cellulitis)
Fever above 38.0 C / 100.4 F or chills
Bleeding from a bite site lasting more than 24 hours
Hives, facial or tongue swelling, throat tightness, or breathing difficulty

What this does NOT mean

This is NOT FDA-cleared for metabolic syndrome.
Anecdotal reports do NOT establish efficacy versus statin, antihypertensive, metformin, or GLP-1 receptor agonist therapy.
It does NOT substitute for lifestyle modification (diet, exercise, weight loss), which is the foundation of management.
It does NOT address individual cardiovascular risk factors that require pharmacologic treatment.
It does NOT mean leech application is safe in patients with poorly controlled diabetes or peripheral arterial disease.

Safety cross-references

Clinical Profile

Category: other
ICD-10: E88.81
Safety tier: medium

Evidence Summary

Metabolic syndrome (NCEP ATP III: at least 3 of abdominal obesity, elevated triglycerides, low HDL, hypertension, impaired fasting glucose) is managed by intensive lifestyle modification (Mediterranean diet, exercise, weight loss) and component-specific pharmacotherapy. No controlled clinical trial of leech therapy for metabolic syndrome has been published; use is investigational only. Proposed effects on waist circumference, triglycerides, or insulin resistance are speculative and would be heavily confounded by concurrent lifestyle changes, and no mechanistic pathway links leech salivary pharmacology to the components of the syndrome.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

Andereya S et al. (2008)0

Detailed Trial Entries

1 trial indexed in the ASH RCT Library with full Study Profile, GRADE rating, and clinical implications:

Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome
Bilden A, Kocak S, Yildiz HT, Cakir F, Kahraman M, Cicek M (2026) · BMC Complementary Medicine and Therapies · n=24 · GRADE low

Contraindications

Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
Hemophilia or other bleeding disorder
Severe anemia (Hb <10 g/dL)
Active bacteremia or sepsis
Known hypersensitivity to leech salivary proteins
Pregnancy (relative — first/third trimester)
Immunocompromised state with severe neutropenia
Diabetic ketoacidosis or HHS (treat first)
Antiplatelet therapy for atherosclerotic cardiovascular disease
Significant hepatic dysfunction (Child-Pugh B/C)
Active cholecystitis or pancreatitis

Related Conditions

Hashimoto's Thyroiditis (Investigational Cervical Adjunct)

Highly investigational adjunct in stable Hashimoto's thyroiditis; case reports only; levothyroxine replacement remains primary.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (Investigational Adjunct)

Investigational adjunct for ME/CFS symptom management; pacing strategies, post-exertional malaise avoidance, and individualized supportive care remain primary; graded exercise therapy is no longer recommended per updated NICE guidance.

Stage III Postsurgical Lymphedema (Highly Investigational Adjunct)

Highly investigational adjunct for advanced postsurgical lymphedema; complete decongestive therapy and (selectively) surgical options (LVA, VLNT) remain evidence-based.

Recurrent Aphthous Stomatitis (Investigational Adjunct)

Investigational adjunct for severe recurrent aphthous stomatitis; topical corticosteroids, chlorhexidine, and (for severe disease) colchicine or systemic immunomodulators remain evidence-based.